• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Michael Singel, PharmD

home / authors / michael-singel-pharmd

Articles

4 experts are featured in this series.

Optimizing Patient Selection with Bispecific Antibodies in Relpased/Refractory Multiple Myeloma

December 8th 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

4 experts are featured in this series.

Linvoseltamab for Patients with Relapsed/Refractory Multiple Myeloma

December 1st 2025

The group describes the clinical gaps that prompted development of bispecifics and summarizes the currently available agents for relapsed/refractory disease.

4 experts are featured in this series.

Key Background Information on Bispecific Antibodies

December 1st 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

4 experts are featured in this series.

Defining Relapse and Switching Therapies in Multiple Myeloma

November 24th 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

4 experts are featured in this series.

First-line Therapy Options in Multiple Myeloma

November 24th 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

4 experts are featured in this series.

Epidemiology and Prognosis of Multiple Myeloma

November 17th 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

4 experts are featured in this series.

Introduction and Pathophysiology of Multiple Myeloma

November 17th 2025

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

© 2025 MJH Life Sciences
AJMC®
All rights reserved.